{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T15:58:37Z","timestamp":1779119917016,"version":"3.51.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T00:00:00Z","timestamp":1511136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["CK14-1402"],"award-info":[{"award-number":["CK14-1402"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"name":"US","award":["U01AI108543-01"],"award-info":[{"award-number":["U01AI108543-01"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.vaccine.2017.11.061","type":"journal-article","created":{"date-parts":[[2017,12,6]],"date-time":"2017-12-06T04:36:15Z","timestamp":1512534975000},"page":"932-938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23\u201324 August 2016"],"prefix":"10.1016","volume":"36","author":[{"given":"Justin R.","family":"Ortiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julian","family":"Hickling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Armen","family":"Donabedian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Othmar G.","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline M.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Neuzil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guus F.","family":"Rimmelzwaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Southern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Spiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Hombach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.11.061_b0005","first-page":"461","article-title":"Vaccines against influenza WHO position paper - November 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Releve epidemiologique hebdomadaire"},{"key":"10.1016\/j.vaccine.2017.11.061_b0010","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1016\/j.vaccine.2017.08.088","article-title":"Data and product needs for influenza immunization programs in low- and middle-income countries: Rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines","volume":"35","author":"Neuzil","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0015","unstructured":"World Health Organization. Preferred product characteristics for next-generation influenza vaccines; 2017 [in press]."},{"key":"10.1016\/j.vaccine.2017.11.061_b0020","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1016\/j.vaccine.2016.02.078","article-title":"Report from the world health organization's product development for vaccines advisory committee (PDVAC) meeting, Geneva, 7\u20139th Sep 2015","volume":"34","author":"Giersing","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0025","article-title":"Report from the world health organization's third product development for vaccines advisory committee (PDVAC) meeting, Geneva, 8\u201310th June 2016","author":"Giersing","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0030","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1016\/j.vaccine.2015.10.014","article-title":"Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5\u20137 May 2014","volume":"33","author":"Cox","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0035","doi-asserted-by":"crossref","first-page":"e0153003","DOI":"10.1371\/journal.pone.0153003","article-title":"Influenza seasonality in the tropics and subtropics - when to vaccinate?","volume":"11","author":"Hirve","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.061_b0040","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/irv.12393","article-title":"Influenza activity in Kenya, 2007\u20132013: timing, association with climatic factors, and implications for vaccination campaigns","volume":"10","author":"Emukule","year":"2016","journal-title":"Influenza Other Respiratory Viruses"},{"key":"10.1016\/j.vaccine.2017.11.061_b0045","doi-asserted-by":"crossref","first-page":"e0152310","DOI":"10.1371\/journal.pone.0152310","article-title":"Temporal patterns of influenza A and B in tropical and temperate countries: what are the lessons for influenza vaccination?","volume":"11","author":"Caini","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.061_b0050","doi-asserted-by":"crossref","first-page":"6493","DOI":"10.1016\/j.vaccine.2015.08.037","article-title":"Considerations of strategies to provide influenza vaccine year round","volume":"33","author":"Lambach","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0055","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QCO.0000000000000392","article-title":"Influenza immunization of pregnant women in resource-constrained countries: an update for funding and implementation decisions","volume":"30","author":"Ortiz","year":"2017","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0060","doi-asserted-by":"crossref","first-page":"4681","DOI":"10.1016\/j.vaccine.2017.07.053","volume":"35","author":"Palache","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0065","doi-asserted-by":"crossref","first-page":"5391","DOI":"10.1016\/j.vaccine.2016.09.023","article-title":"Preparing for the unpredictable: The continuing need for pandemic influenza preparedness","volume":"34","author":"Gellin","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0070","doi-asserted-by":"crossref","first-page":"5420","DOI":"10.1016\/j.vaccine.2016.07.047","article-title":"Challenges and successes for the grantees and the technical advisory group of WHO's influenza vaccine technology transfer initiative","volume":"34","author":"Grohmann","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0075","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: Analysis of the 2014 WHO\/UNICEF joint reporting form on immunization","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0080","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1016\/j.vaccine.2016.03.085","article-title":"Universal influenza vaccines: Shifting to better vaccines","volume":"34","author":"Berlanda Scorza","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0085","unstructured":"Global Alliance for Vaccines and Immunisation (GAVI). Final vaccine investment strategy analysis 2013: maternal influenza. Geneva, Switzerland: Global Alliance for Vaccines and Immunisation (GAVI); 2013."},{"key":"10.1016\/j.vaccine.2017.11.061_b0090","series-title":"Vaccine presentation and packaging advisory group (VPPAG)","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.vaccine.2017.11.061_b0095","unstructured":"World Health Organization. Assessing the programmatic suitability of vaccine candidates for WHO prequalification. In: Organization WH, editor. Geneva, Switzerland: World Health Organization; 2016."},{"key":"10.1016\/j.vaccine.2017.11.061_b0100","first-page":"261","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2015: conclusions and recommendations","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Releve epidemiologique hebdomadaire"},{"key":"10.1016\/j.vaccine.2017.11.061_b0105","doi-asserted-by":"crossref","first-page":"e0118884","DOI":"10.1371\/journal.pone.0118884","article-title":"Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009\u20132013","volume":"10","author":"Cohen","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.061_b0110","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/infdis\/jiv100","article-title":"Severe acute respiratory illness deaths in Sub-Saharan Africa and the role of influenza: a case series from 8 countries","volume":"212","author":"McMorrow","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0115","doi-asserted-by":"crossref","unstructured":"GBD 2015 mortality and causes of death collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980\u20132015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet (London, England). 2016; 388: 1459\u2013544.","DOI":"10.1016\/S0140-6736(16)31012-1"},{"key":"10.1016\/j.vaccine.2017.11.061_b0120","doi-asserted-by":"crossref","unstructured":"Nair H, Brooks WA, Katz M, Roca A, Berkley JA, Madhi SA, et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet (London, England). 2011; 378: 1917\u201330.","DOI":"10.1016\/S0140-6736(11)61051-9"},{"key":"10.1016\/j.vaccine.2017.11.061_b0125","doi-asserted-by":"crossref","first-page":"e1001977","DOI":"10.1371\/journal.pmed.1001977","article-title":"Global role and burden of influenza in pediatric respiratory hospitalizations, 1982\u20132012: a systematic analysis","volume":"13","author":"Lafond","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2017.11.061_b0130","unstructured":"World Health Organization. Global routine vaccination coverage; 2011."},{"key":"10.1016\/j.vaccine.2017.11.061_b0135","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.pcl.2017.03.007","article-title":"Influenza: a global perspective","volume":"64","author":"Rotrosen","year":"2017","journal-title":"Pediatric Clinics of North America"},{"key":"10.1016\/j.vaccine.2017.11.061_b0140","doi-asserted-by":"crossref","first-page":"6146","DOI":"10.1016\/j.vaccine.2014.08.068","article-title":"Enhanced and persistent antibody response against homologous and heterologous strains elicited by a MF59-adjuvanted influenza vaccine in infants and young children","volume":"32","author":"Nolan","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0145","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari","year":"2011","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.11.061_b0150","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/INF.0b013e31819d6394","article-title":"Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant","volume":"28","author":"Vesikari","year":"2009","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.11.061_b0155","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2017.04.029","article-title":"A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines","volume":"35","author":"Chada","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0160","unstructured":"National Advisory Committee on Immunization (Canada). Literature review on pediatric Fluad\u00ae influenza vaccine use in children 6-72 months of age; 2015."},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2017.11.061_b0165","doi-asserted-by":"crossref","first-page":"S120","DOI":"10.1016\/j.cmi.2015.12.005","article-title":"Universal influenza vaccines: a realistic option?","volume":"22","author":"de Vries","year":"2016","journal-title":"Clin Microbiol Infect: Official Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0170","unstructured":"Graham B. Towards a universal influenza vaccine. In: Presentation at WHO product development for vaccines advisory committee meeting Geneva, Switzerland: World Health Organization; 2014."},{"key":"10.1016\/j.vaccine.2017.11.061_b0175","series-title":"Presentation at WHO product development for vaccines advisory committee (PD-VAC) meeting Geneva","author":"Graham","year":"2015"},{"key":"10.1016\/j.vaccine.2017.11.061_b0180","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.1016\/j.amepre.2015.09.012","article-title":"Prospects for broadly protective influenza vaccines","volume":"49","author":"Treanor","year":"2015","journal-title":"Am J Preventive Med"},{"key":"10.1016\/j.vaccine.2017.11.061_b0185","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3389\/fimmu.2016.00195","article-title":"Heterosubtypic T-cell immunity to influenza in humans: challenges for universal T-cell influenza vaccines","volume":"7","author":"Sridhar","year":"2016","journal-title":"Frontiers Immunol"},{"key":"10.1016\/j.vaccine.2017.11.061_b0190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/irv.12445","article-title":"Workshop report: Immunoassay standardisation for \u201cuniversal\u201d influenza vaccines","volume":"11","author":"Pavlova","year":"2017","journal-title":"Influenza Other Respiratory Viruses"},{"key":"10.1016\/j.vaccine.2017.11.061_b0195","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1093\/infdis\/jiw262","article-title":"Generation and protective ability of influenza virus-specific antibody-dependent cellular cytotoxicity in humans elicited by vaccination, natural infection, and experimental challenge","volume":"214","author":"Jegaskanda","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0200","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3390\/vaccines3020293","article-title":"Measuring cellular immunity to influenza: methods of detection, applications and challenges","volume":"3","author":"Coughlan","year":"2015","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2017.11.061_b0205","doi-asserted-by":"crossref","first-page":"26494","DOI":"10.1038\/srep26494","article-title":"ICOS(+)PD-1(+)CXCR3(+) T follicular helper cells contribute to the generation of high-avidity antibodies following influenza vaccination","volume":"6","author":"Bentebibel","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2017.11.061_b0210","doi-asserted-by":"crossref","first-page":"e0157066","DOI":"10.1371\/journal.pone.0157066","article-title":"Early rise of blood T follicular helper cell subsets and baseline immunity as predictors of persisting late functional antibody responses to vaccination in humans","volume":"11","author":"Spensieri","year":"2016","journal-title":"PloS One"},{"key":"10.1016\/j.vaccine.2017.11.061_b0215","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/irv.12068","article-title":"The consortium for the standardization of influenza seroepidemiology (CONSISE): a global partnership to standardize influenza seroepidemiology and develop influenza investigation protocols to inform public health policy","volume":"7","author":"Van Kerkhove","year":"2013","journal-title":"Influenza Other Respiratory Viruses"},{"key":"10.1016\/j.vaccine.2017.11.061_b0220","unstructured":"FLUCOP. Standardisation and development of assays for assessment of influenza vaccine correlates of protection; 2015. Available at http:\/\/www.flucop.eu\/."},{"key":"10.1016\/j.vaccine.2017.11.061_b0225","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2016.10.040","article-title":"Influenza vaccine research funded by the European commission FP7-health-2013-innovation-1 project","volume":"34","author":"Liu","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0230","doi-asserted-by":"crossref","unstructured":"Benoit A, Beran J, Devaster JM, Esen M, Launay O, Leroux-Roels G, et al. Hemagglutination inhibition antibody titers as a correlate of protection against seasonal A\/H3N2 influenza disease. Open Forum Infectious Diseases 2015; 2: ofv067.","DOI":"10.1093\/ofid\/ofv067"},{"key":"10.1016\/j.vaccine.2017.11.061_b0235","first-page":"18","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int J Infect Dis: IJID: Official Publ Int Soc Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0240","doi-asserted-by":"crossref","unstructured":"Wright PF, Hoen AG, Ilyushina NA, Brown EP, Ackerman ME, Wieland-Alter W, et al. Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infectious Diseases 2016; 3: ofw108.","DOI":"10.1093\/ofid\/ofw108"},{"key":"10.1016\/j.vaccine.2017.11.061_b0245","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1080\/21645515.2015.1052196","article-title":"Dissecting the indirect effects caused by vaccines into the basic elements","volume":"11","author":"Scarbrough Lefebvre","year":"2015","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2017.11.061_b0250","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1016\/j.vaccine.2013.05.017","article-title":"Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France)","volume":"31","author":"Gessner","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0255","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa052664","article-title":"Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine","volume":"354","author":"Vesikari","year":"2006","journal-title":"New Engl J Med"},{"key":"10.1016\/j.vaccine.2017.11.061_b0260","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S1473-3099(13)70046-X","article-title":"AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial","volume":"13","author":"McElhaney","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0265","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S1473-3099(16)00129-8","article-title":"Variable influenza vaccine effectiveness by subtype: a systematic review and meta-analysis of test-negative design studies","volume":"16","author":"Belongia","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2017.11.061_b0270","doi-asserted-by":"crossref","first-page":"e318","DOI":"10.1097\/INF.0000000000001280","article-title":"Effectiveness of the 2013 and 2014 southern hemisphere influenza vaccines against laboratory-confirmed influenza in young children using a test-negative design, Bangkok, Thailand","volume":"35","author":"Kittikraisak","year":"2016","journal-title":"Pediatric Infect Dis J"},{"key":"10.1016\/j.vaccine.2017.11.061_b0275","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1586\/14760584.2014.966695","article-title":"Potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review","volume":"13","author":"Sullivan","year":"2014","journal-title":"Expert Rev Vaccines"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2017.11.061_b0280","doi-asserted-by":"crossref","first-page":"F1","DOI":"10.1016\/j.vaccine.2015.10.080","article-title":"The safety of influenza vaccines in children: an institute for vaccine safety white paper","volume":"33","author":"Halsey","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.11.061_b0285","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.4161\/21645515.2014.972149","article-title":"Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials","volume":"10","author":"Vaughn","year":"2014","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"10.1016\/j.vaccine.2017.11.061_b0290","unstructured":"European Medicines Agency. Guideline on influenza vaccines, non-clinical and clinical Module; 2016."},{"key":"10.1016\/j.vaccine.2017.11.061_b0295","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/irv.12351","article-title":"A review of the changes to the licensing of influenza vaccines in Europe","volume":"10","author":"Wijnans","year":"2016","journal-title":"Influenza Other Respiratory Viruses"},{"key":"10.1016\/j.vaccine.2017.11.061_b0300","doi-asserted-by":"crossref","unstructured":"Feikin DR, Scott JA, Gessner BD. Use of vaccines as probes to define disease burden. Lancet (London, England). 2014; 383: 1762\u201370.","DOI":"10.1016\/S0140-6736(13)61682-7"},{"key":"10.1016\/j.vaccine.2017.11.061_b0305","doi-asserted-by":"crossref","unstructured":"Nunes MC, Cutland CL, Jones S, Downs S, Weinberg A, Ortiz JR, et al. Efficacy of maternal influenza vaccination against all-cause lower respiratory tract infection hospitalizations in young infants: Results from a randomized controlled trial. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America; 2017.","DOI":"10.1093\/cid\/cix497"},{"key":"10.1016\/j.vaccine.2017.11.061_b0310","unstructured":"World Health Organization. Global vaccine action plan 2011\u20132020; 2013."},{"key":"10.1016\/j.vaccine.2017.11.061_b0315","doi-asserted-by":"crossref","unstructured":"Gibson E, Begum N, Martinon-Torres F, Safadi MA, Sackeyfio A, Hackett J, et al. Cost-effectiveness analysis of the direct and indirect impact of intranasal live attenuated influenza vaccination strategies in children: alternative country profiles. J Market Access Health Policy 2016; 4.","DOI":"10.3402\/jmahp.v4.31205"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17316456?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17316456?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:24:39Z","timestamp":1759400679000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17316456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":63,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0264410X17316456"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.061","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Report on eighth WHO meeting on development of influenza vaccines that induce broadly protective and long-lasting immune responses: Chicago, USA, 23\u201324 August 2016","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.11.061","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 World Health Organization. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}